Lei Lai diet pill orforglipron late-stage trials meet standards, paving the way for global approval.

The company Rilai stated on Tuesday that its daily weight-loss pill helped obese and type 2 diabetes patients to lose weight in late-stage trials, meeting the primary goal of the study and paving the way for the company to seek approval for the drug globally. This treatment method is gradually becoming a new needle-free alternative in the lucrative market for weight-loss and diabetes drugs known as GLP-1s. The more convenient pill form can increase the supply of treatment, and is easier to obtain compared to the expensive weekly injection treatments currently dominating the market. Unlike similar oral treatments from main competitor Novo Nordisk, Rilai's pill does not require dietary restrictions. In the 72-week trial period, the highest dose of the oral drug orforglipron helped patients to average a 10.5% weight loss, while those on a placebo only lost 2.2% of their weight. When all patients were included in the analysis, the weight loss effect of the drug was 9.6%.